The European Medicines Agency confirmed it will turn an EU-level trial advice pilot into a permanent option for sponsors, extending the mechanism that provides regulator input during development planning. The change is aimed at continuing structured guidance at scale for clinical trials across member states. For biotech and pharma teams, the shift matters because early scientific advice can tighten protocol design and reduce downstream execution friction—particularly in complex programs that require alignment across multiple jurisdictions.